An observational study in Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm Without Rupture and Radiation Exposure, sponsored by Clinical Centre of Serbia. Not yet recruiting at 1 site in Serbia. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-11-20.
Sponsored by Clinical Centre of Serbia · Observational
Short-term results are favorable for EndoVascular Aneurysm Repair (EVAR) compared to open surgery. One of the major drawbacks to this shift is the need for fluoroscopy and contrast dyes to visualise endovascular devices. The use of fluoroscopy exposes both patients and caregivers to harmful ionizing radiation. Because of the harmful effects of radiation, recent radiation protection guidelines strongly recommend as low as reasonably achievable (ALARA) principle. The need for additional radiation-reducing navigation techniques is high, with the ultimate goal of performing endovascular procedures without radiation at all.
In response to these challenges, Centerline Biomedical (Cleveland, Ohio, USA) has developed a proprietary electromagnetic tracking and positioning system called the Intra-Operative Positioning System (IOPS). This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the radiation exposure for patients and healthcare professionals. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed.
This study aims to describe the influence of IOPS technology on radiation exposure during cannulation of the contralateral limb (CL) during standard EVAR.
Background:
The current standard of care for abdominal aortic aneurysm (AAA) is endovascular aneurysm repair (EVAR) which has been suggested as the treatment of choice by both European and American guidelines . Although short-term results are favorable for EVAR compared to open surgery, one of the major drawbacks to this shift is the need for fluoroscopy and contrast dyes to visualise endovascular devices. The contrast dyes used during these procedures can induce renal failure in patients with preexisting renal dysfunction. Meanwhile, the use of fluoroscopy exposes both patients and caregivers to harmful ionizing radiation. Because of the harmful effects of radiation, recent radiation protection guidelines strongly recommend as low as reasonably achievable (ALARA) principle.
In response to these challenges, Centerline Biomedical (Cleveland, Ohio, USA) has developed a proprietary electromagnetic tracking and positioning system called the Intra-Operative Positioning System (IOPS). This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the use of contrast dye and radiation exposure for patients and healthcare professionals alike. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. Image guidance is provided using 3D maps of the vasculature, generated from thin-slice contrast-enhanced preoperative computerised tomography angiography (CTA). At the start of the procedure, a self-adhesive sterile fiducial tracking pad is attached to the patient's lumbar region, and the angiography system is used to perform a non-contrast-enhanced cone-beam CT scan. The cone beam CT volume is then loaded onto the IOPS cart and manually aligned with the preoperative CT volume. This work can be performed in parallel with achieving vascular access, with minimal effects on the procedure time. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The console is operated by a technician under a physician's instruction. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed. This technology has been used by other centres for visceral and renal cannulation during complex aortic aneurysm procedures.
Previously there have been publications on the use of Fiber Optic Real Shape (FORS) Technology with both complex and standard endovascular aneurysm repair (EVAR) showing the potential benefit of this technology in procedural time and radiation reduction. However, the need for additional radiation-reducing navigation techniques is high, with the ultimate goal of performing endovascular procedures without radiation at all.
This study aims to describe the influence of IOPS technology on radiation exposure during cannulation of the contralateral limb (CL) during standard EVAR.
Study outcome and sample size:
Technical success of using IOPS technology during cannulation of CL Navigation time expressed through total procedural time, CL cannulation time, fluoroscopy time (overall and during CL cannulation) Radiation exposure parameters that were described in the latest European Society for Vascular Surgery (ESVS) radiation guidelines: cumulative air kerma (CAK), kerma area product (KAP), fluoroscopy time (FT) (4) To ensure sufficient statistical power to answer hypothetical questions, 80 subjects will be entered into the database. Navigation time and radiation exposure parameters are used to calculate the sample size. Assuming the difference in terms of both parameters, 30 patients are required in each arm to achieve a statistical power of 85% at p=0.05. With two arms (conventional and IOPS group), assuming a 20% rate of missing data, a total N of 80 patients is required.
Research Design:
This prospective study includes patients with standard AAA undergoing EVAR within instructions for use (IFU) treated from September 1st, 2024 until May 1st, 2025 at the Clinic for Vascular and Endovascular Surgery, University Clinical Centre of Serbia.
Procedures Involved:
This study will not impact the care that patients receive. Patient data will be compiled and analyzed to accomplish the proposed study objectives. Data collection will include demographic information, patient-related factors, comorbidities, diagnostic imaging information (describing the morphology of the aortoiliac segment), and periprocedural information related to the timing and radiation.
Data management:
After the data has been collected at a participating institution, the data will be transmitted to an online database which will be available only to a central analytic center located at the Clinic for Vascular and Endovascular Surgery/University Clinical Center of Serbia/Medical Faculty, University of Belgrade.
Risks to Subjects:
As this is a prospective observational study performing EVAR in standard AAA using new radiation protection technology for visualisation of wires and catheters in a newly equipped angio suite, there are minimal potential physical risks to subjects. There is also a minimal risk of breach of confidentiality that could occur when patient information is collected and analyzed for the proposed study. However, appropriate measures will be taken to minimize the risk as much as possible. All information recorded will be de-identified. This study will abide by all regulations related to protecting human subjects and protected health information.
Potential Benefits to Subjects:
There is a potential benefit to the subjects involved in the IOPS group. Hypothetically they will have lower procedural times and lower radiation doses during CL cannulation. Future patients treated with this technology might have reduced radiation and cannulation times. This will make it possible to perform more and more procedures with a minimal amount of radiation, or even without radiation at all.
Statistics and Data Analysis:
Continuous variables will be described using the median and interquartile range or mean and standard deviation. Categorical variables will be described using frequencies and percentages. Group comparisons will be performed by using the Student t-test or Mann-Whitney U test, as appropriate. Categorical data will be expressed as percentages and will be compared using the chi-square test or Fisher exact test. Differences will be considered statistically significant at p \< 0.05. Analyses will be performed using SPSS software, version 28.0 (SPSS, Chicago, ILLINOIS, USA).
Conflict of Interest:
Since this is a physician-initiated trial, the investigators have no conflict of interest to report.
Funding Source:
There are no plans to apply for additional grants or additional funding. No funding is required for the completion of this study.
Publication Plan:
All research personnel included in this project will be eligible for authorship in any resulting abstracts and publications following the qualifications outlined by the International Committee of Medical Journal Editors. The order of authors will be determined prior to manuscript development and depend on each individual's contribution to the study.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
This study's planned enrollment of 80 is below the median of 165 across 217 observational studies indexed under Aortic Aneurysm, Abdominal.
Browse Aortic Aneurysm, Abdominal studies →Clinical Centre of Serbia is the lead sponsor of 24 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with infrarenal AAA undergoing standard EVAR according to the IFUs of the manufacturer will be stratified into two groups:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with AAA undergoing standard EVAR according to the IFU using IOPS technology for visulisation of guidewires and catheter for the cannulation of contralateral limb.
Device: Intra-Operative Positioning System (IOPS)
Patients with AAA undergoing standard EVAR according to the IFU using standardised approach and materials.
Device: Conventional group
This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the use of contrast dye and radiation exposure for patients and healthcare professionals alike. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The console is operated by a technician under a physician's instruction. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed.
This group will be treated using standardised materials (wires, catheters) during EVAR.
Fluoroscopic time per participant required for cannulation
Record cumulative fluoroscopy time reported by fluoroscopic system before and after cannulation of contralateral limb
Time frame: Cannulation of contralateral limb during the intervention
Number of participants with technical success of gate catheterisation
Definition of technical success with fluoroscopy: Cannulation completed retrograde; Definition of technical success with IOPS: Cannulation completed retrograde using IOPS catheter
Time frame: Cannulation of contralateral limb during the intervention
Clock time per participant required for cannulation
Use stopwatch, or record clock time before and after cannulation of contralateral limb
Time frame: Cannulation of contralateral limb during the intervention
Radiation dose per participant during cannulation
Cumulative air kerma \[CAK\], air kerma area product \[KAP\], excluding digital subtraction angiography time
Time frame: Record radiation reported by fluoro system before and after cannulation of contralateral limb during the intervention
Plan to share: Undecided — This will be decided among the study group, once study has been completed.
Start is estimated for Jan 2025; primary completion for Sep 2025, 7 months later.
Of 67 non-industry observational studies under Aortic Aneurysm, Abdominal, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 83. This study's planned 7 months is below that.
Counting every sponsor, half of 91 studies reached it within 48 months; a quarter within 24 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinical Centre of Serbia